Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate

Cancer

Volumn 106, Issue 12, 2006, Pages 2617-2623

  Mackler, Niklas J ^a   Dunn, Rodney L ^b   Hellerstedt, Beth ^a   Cooney, Kathleen A ^a,b   Fardig, Judith ^a   Olson, Karin ^a   Pienta, Kenneth J ^a,b   Smith, David C ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c 7302 CCGC 0946 ^*  (United States)

Author keywords

Adult medical oncology; Biochemical resistant; Clinical trials; Phase I trials; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EMCYST; ESTRAMUSTINE; NAVELBINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERKALEMIA; INCONTINENCE; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PAIN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT OBSTRUCTION;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ESTRAMUSTINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VINBLASTINE;

EID: 33745197160     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21927     Document Type: Article

References (20)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
3. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351:1513-1520.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
6. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 1992;52:4433-4440.
7. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992;10: 1754-1761.
8. Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol. 1992;147:931-934.
9. Binet S, Chaineau E, Fellous A, et al. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer. 1990;46: 262-266.
10. Carles J, Domenech M, Gelabert-Mas A, et al. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol. 1998;37: 187-191.
11. Sweeney CJ, Monaco FJ, Jung SH, et al. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol. 2002;13:435-440.
12. Freyer G, Delozier T, Lichinister M, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003;21:35-40.
13. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med. 1995;14:1149-1161.
14. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics. 1996;52:673-684.
15. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics. 2000;56:1177-1182.
16. Smith MR, Kaufman D, Oh W, et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. Cancer. 2000;89:1824-1828.
17. Borrega P, Velasco A, Bolanos M, et al. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer. Urol Oncol. 2004;22:32-35.
18. Hellerstedt B, Pienta KJ, Redman BG, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003;98:1603-1610.
19. Pienta KJ, Fisher EI, Eisenberger MA, et al. A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9407). Prostate. 2001;46:257-261.
20. Sumiyoshi Y, Hashine K, Nakatsuzi H, Yamashita Y, Karashima T. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer. Int J Urol. 2000;7:243-247.